Moaligou Camille, Dion Michel, Ishnaiwer Murad, Dailly Éric, Batard Éric, Javaudin François
Cibles et médicaments des infections et de l'immunité, IICiMed, UR 1155, Nantes Université, Nantes 44000, France.
Clinical Pharmacology Department, Nantes University Hospital, Nantes 44000, France.
J Appl Microbiol. 2023 Oct 4;134(10). doi: 10.1093/jambio/lxad223.
The main objective of this study was to compare extended-spectrum β-lactamase (ESBL) Escherichia coli fecal titers during 12 days between two groups: mice who received proton pump inhibitors (PPIs) and those that did not.
We tested three different in vivo models: model 1, high inoculum (106 CFU ml-1); model 2, low inoculum (102 CFU ml-1); and model 3, low inoculum and 2-day amoxicillin wash-out. There was no significant difference between the two groups in fecal ESBL E. coli titers in models 1 and 2. The fecal titers of ESBL E. coli were probably too high to show differences in colonization related to PPI treatment. By introducing a 2-day wash-out period after stopping amoxicillin (model 3), the fecal ESBL E. coli titers were higher in the PPI-treated mice during 12 days (3 log versus 11 log day CFU g-1; P < 0.05). This result highlighted that PPIs promote stable ESBL E. coli digestive carriage in mice. Fecal quantitative PCR showed that mice with low ESBL E. coli fecal titers had a much higher concentration of equol-producing bacteria, Muribaculum sp., and Adlercreutzia caecimuris.
Pantoprazole treatment promotes sustained digestive carriage of ESBL E. coli in amoxicillin-treated mice.
本研究的主要目的是比较两组小鼠在12天内超广谱β-内酰胺酶（ESBL）大肠杆菌粪便滴度：接受质子泵抑制剂（PPI）的小鼠和未接受质子泵抑制剂的小鼠。
我们测试了三种不同的体内模型：模型1，高接种量（106 CFU/ml-1）；模型2，低接种量（102 CFU/ml-1）；以及模型3，低接种量并进行2天阿莫西林洗脱。在模型1和模型2中，两组之间的粪便ESBL大肠杆菌滴度没有显著差异。ESBL大肠杆菌的粪便滴度可能过高，无法显示与PPI治疗相关的定植差异。通过在停止阿莫西林后引入2天的洗脱期（模型3），在12天内，接受PPI治疗的小鼠粪便ESBL大肠杆菌滴度更高（3 log对11 log日CFU/g-1；P<0.05）。这一结果突出表明，PPI促进了小鼠体内ESBL大肠杆菌的稳定消化携带。粪便定量PCR显示，ESBL大肠杆菌粪便滴度低的小鼠中，产雌马酚细菌、Muribaculum菌属和盲肠阿德勒克雷茨菌的浓度要高得多。
泮托拉唑治疗可促进阿莫西林治疗的小鼠体内ESBL大肠杆菌的持续消化携带。
